

MARKET REPORT



Intravenous Immunoglobulin Market, By Disease Types (CIDP, Hypogammaglobulinemia, Congenital AIDS, Immunodeficiency diseases, Chronic Lymphocytic Leukaemia, Myasthenia Gravis, Multifocal motor neuropathy, and others), By Route (Intravenous and Subcutaneous) And Geography (North America, Europe, Asia Pacific, And Rest Of The World) - Analysis, Share, Trends, Size, & Forecast From 2016 - 2027- C

BioPortfolio

Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



AnalystView
Market Insights

Intravenous Immunoglobulin Market, By Disease Types (CIDP, Hypogammaglobulinemia, Congenital AIDS, Immunodeficiency diseases, Chronic Lymphocytic Leukaemia, Myasthenia Gravis, Multifocal motor neuropathy, and others), By Route (Intravenous and Subcutaneous) And Geography (North America, Europe, Asia Pacific, And Rest Of The World) – Analysis, Share, Trends, Size, & Forecast From 2016 – 2027- C

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** bioportfolio97@gmail.com

Intravenous Immunoglobulin Market, By Disease Types (CIDP, Hypogammaglobulinemia, Congenital AIDS, Immunodeficiency diseases, Chronic Lymphocytic Leukaemia, Myasthenia Gravis, Multifocal motor neuropathy, and others), By Route (Intravenous and Subcutaneous) And Geography (North America, Europe, Asia Pacific, And Rest Of The World) – Analysis, Share, Trends, Size, & Forecast From 2016 – 2027- C

REPORT HIGHLIGHT

The intravenous immunoglobulin market is estimated to represent a global market of USD 8,306 million by 2019 with growth rate of 6.3%. Intravenous immunoglobulin (IVIg) is an antibody-based product that can be administered intravenously. It contains the pooled immunoglobulin G, derived from the plasma. In terms of types, these products are categorized as immunoglobulin A, immunoglobulin G, immunoglobulin M, immunoglobulin D, and immunoglobulin E, divided based on the variety of heavy chain these molecules contain. IVIg therapy is basically indicated to the patients with humoral immunodeficiency or whose body does not produce enough antibodies. IVIg therapy act by providing extra antibodies which last for several weeks and help patients to fight against various infectious diseases. Alternatively, the immunoglobulin therapy can provide through subcutaneous route (as an injection under the skin) or intramuscular route.

Market Dynamics

Intravenous Immunoglobulin (IVIg) and Subcutaneous Immunoglobulin (SCIG) are preferred for treatment of autoimmune diseases. The growth of this market is primarily attributed to the increasing incidences bleeding and autoimmune disorders, aging population, and development of new treatment indications such as myasthenia gravis. However, high cost coupled with stringent regulations associated with IVIg therapy hampers the market growth over the future period.

COVID-19 Impact

The proposed reports analyse and evaluates the COVID-19 impact, and anticipated change on the future market scenario on this industry, by taking into the account the economic, political, technological, and social, parameters.

Disease Types Takeaway

IVIg therapy is widely used for the treatment of many autoimmune diseases. Based on the disease types, the market is divided as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Hypogammaglobulinemia, Congenital AIDS, Immunodeficiency diseases, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal motor neuropathy, and others. In 2019, Hypogammaglobulinemia is considered to be the largest market, accounted for the 1.6 billion during the same year. It is an immune disorder, characterized by the low level of immunoglobulin and mature B-lymphocytes and plasma cells. This condition can be treated by the replacement of immunoglobulin by subcutaneous or intravenous therapies with antibiotics. IVIg therapy for the treatment of Congenital AIDS is growing significantly, i.e. 7.9% over the forecast period. In terms of route of administration, intravenous route of administration captured the largest share of the total market, around 80.1% in 2019.

Regional Takeaway

Regionally, North America is considered to be the major market, capturing around 47% share across the year owing to the rise in the incidence of autoimmune diseases. According to the American Autoimmune Related Disease Association, Inc. (AARDA), about 50 million Americans were suffered from autoimmune diseases in the year 2012 and the number is expected to grow over the forecast period.

Developing regions such as Asia Pacific, and Latin America is accounted for the significant revenue share due to the favourable government initiatives. For example, in September 2013, Japanese Ministry of Health, Labour and Welfare have approved Hizentra, subcutaneous immunoglobulin therapy.

Key Vendor Takeaway

Companies such as Shire, Octapharma, CSL. Grifols and others are profiled in a study. Increasing research and development initiatives coupled with growing revenue generation from IVIG business by leading players have attracted many companies to invest in this market. For example, CSL recorded around USD 2,320 million from its immunoglobulin business segment in 2014, up 12% compared to the previous year.

In March 2010, the U.S. FDA approved Hizentra, company's subcutaneous immunoglobulin product which has contributed strong sale in the U.S. and European market. Strong growth is majorly attributed to its convenience in self-administration along with the introduction of co-pay relief program. In addition to this, the recent approval of Hizentra for treatment of primary and secondary immune deficiencies in Japan coupled with the expansion of bi-weekly administration label in the U.S. market has supported the revenue generation. Furthermore, the company achieved strong growth with Privigen and Carimune sale in the Europe and America respectively.

The market size and forecast for each segment has been provided for the period 2016 to 2027, considering 2019 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2021 to 2027 for every reported segment.

The years considered for the study are:

Historical Year - 2016 to 2018

Base Year - 2019

Estimated Year - 2020

Projected Year - 2027

Additional Details

Publisher : AnalystView

Reference : AV147

Number of Pages : 180

Report Format : PDF

Publisher Information :



AnalystView Market Insights is a market research and consulting firm that adopts a proactive approach to provide the diverse need for accurate and precise market research, custom research, and consulting solutions across geographies and industry verticals. Our company is led by a team of passionate, naturally curious, and strategic thinkers from different industry backgrounds.

These experts are dedicated to creating concrete market data analysis in various industries such as Healthcare, Bulk Chemicals, Semiconductors and Electronics, Foods and Beverages. We strive to develop meaningful and evidence-based research data that helps our clients, empowering organizations and brands of all sizes with strategic analysis, accurate data, and consumer trends.

We aim to be the number one choice for various clients who require credible data to make vital business decisions. We wish to be a trusted and reliable analytics partner to major business organizations.

We understand that critical business decisions can be taken only when verified, authentic information is available. Therefore, our experts work meticulously to provide our clients with the accurate data, so that they need not spend time in verifying it.

It is also our goal to help our clients ignore traditional research methods that require a large amount of capital, manpower, and most important of it all – the time. We know that these factors are precious to a company and always follow the latest research techniques that produce the required result in a short span of time.

Table Of Contents for Intravenous Immunoglobulin Market, By Disease Types (CIDP, Hypogammaglobulinemia, Congenital AIDS, Immunodeficiency diseases, Chronic Lymphocytic Leukaemia, Myasthenia Gravis, Multifocal motor neuropathy, and others), By Route (Intravenous and Subcutaneous) And Geography (North America, Europe, Asia Pacific, And Rest Of The World) – Analysis, Share, Trends, Size, & Forecast From 2016 – 2027- C

- TABLE OF CONTENT1. INTRAVENOUS IMMUNOGLOBULIN MARKET OVERVIEW1.1. Study Scope1.2. Base Year1.3. Assumption and Methodology2. EXECUTIVE SUMMARY2.1. Key Market Facts2.2. Geographical Scenario2.3. Companies in the Market3. INTRAVENOUS IMMUNOGLOBULIN KEY MARKET TRENDS3.1. Market Drivers3.1.1. Impact Analysis of Market Drivers3.2. Market Restraints3.2.1. Impact Analysis of Market Restraints3.3. Market Opportunities3.4. Market Future Trends4. INTRAVENOUS IMMUNOGLOBULIN INDUSTRY STUDY4.1. Company Activity Analysis4.2. Regulatory Framework Analysis4.3. Market Attractiveness Analysis4.4. Value Chain Analysis5. INTRAVENOUS IMMUNOGLOBULIN MARKET LANDSCAPE5.1. Market Share Analysis5.2. Key Innovators6. INTRAVENOUS IMMUNOGLOBULIN MARKET – BY DISEASE TYPES:6.1. Overview6.2. CIDP6.2.1. Overview6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)6.3. Hypogammaglobulinemia6.3.1. Overview6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)6.4. Congenital AIDS6.4.1. Overview6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)6.5. Immunodeficiency diseases6.5.1. Overview6.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)6.6. Chronic Lymphocytic Leukaemia6.6.1. Overview6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)6.7. Myasthenia Gravis6.7.1. Overview6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)6.8. Multifocal motor neuropathy6.8.1. Overview6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)6.9. Others6.9.1. Overview6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)7. INTRAVENOUS IMMUNOGLOBULIN MARKET – BY ROUTE OF ADMINISTRATION:7.1. Overview7.2. Intravenous7.2.1. Overview7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)7.3. Subcutaneous7.3.1. Overview7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)8. INTRAVENOUS IMMUNOGLOBULIN MARKET- BY GEOGRAPHY8.1. Introduction8.2. North America8.2.1. Overview8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)8.2.3. U.S.8.2.3.1. Overview8.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)8.2.4. Canada8.2.4.1. Overview8.2.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)8.3. Europe8.3.1. Overview8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)8.3.3. France8.3.3.1. Overview8.3.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)8.3.4. Germany8.3.4.1. Overview8.3.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)8.3.5. Rest of Europe8.3.5.1. Overview8.3.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)8.4. Asia Pacific (APAC)8.4.1. Overview8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)8.4.3. China8.4.3.1. Overview8.4.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)8.4.4. India8.4.4.1. Overview8.4.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)8.4.5. Rest of APAC8.4.5.1. Overview8.4.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)8.5. Rest of the World8.5.1. Overview8.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)8.5.3. Latin America8.5.3.1. Overview8.5.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)8.5.4. Middle East and Africa8.5.4.1. Overview8.5.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)9. KEY VENDOR ANALYSIS9.1. Shire9.1.1.

Company Overview9.1.2. SWOT Analysis9.1.3. Key Developments9.2. Octapharma9.2.1. Company
Overview9.2.2. SWOT Analysis9.2.3. Key Developments9.3. CSL9.3.1. Company Overview9.3.2. SWOT
Analysis9.3.3. Key Developments9.4. Grifols9.4.1. Company Overview9.4.2. SWOT Analysis9.4.3. Key
Developments9.5. China Biologics Products, Inc.9.5.1. Company Overview9.5.2. SWOT Analysis9.5.3. Key
Developments*Client can request additional company profiling as per specific requirements10. 360 DEGREE
ANALYSTVIEW11. APPENDIX11.1. Research Methodology11.2. Abbreviations11.3. Disclaimer11.4. Contact Us

List Of Tables in Intravenous Immunoglobulin Market, By Disease Types (CIDP, Hypogammaglobulinemia, Congenital AIDS, Immunodeficiency diseases, Chronic Lymphocytic Leukaemia, Myasthenia Gravis, Multifocal motor neuropathy, and others), By Route (Intravenous and Subcutaneous) And Geography (North America, Europe, Asia Pacific, And Rest Of The World) – Analysis, Share, Trends, Size, & Forecast From 2016 – 2027- C

List of Tables

Table 1 List of Acronyms

Table 2 Key Market Facts, 2016 – 2027

Table 3 Market Drivers: Impact Analysis

Table 4 Market Restraint: Impact Analysis

Table 5 Market Opportunity: Impact Analysis

Table 6 PESTLE Analysis

Table 7 Porter’s Five Forces Analysis

Table 8 Company Market Share Analysis

Table 9 Global Intravenous Immunoglobulin Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US\$ Million)

Table 10 Intravenous Immunoglobulin Market, by Disease Types, 2016 – 2027 (USD Million)

Table 11 Intravenous Immunoglobulin Market, by Geography, 2016 – 2027 (USD Million)

Table 12 North America Intravenous Immunoglobulin Market, 2016 – 2027 (USD Million)

Table 13 U.S. Intravenous Immunoglobulin Market, 2016 – 2027 (USD Million)

Table 14 Canada Intravenous Immunoglobulin Market, 2016 – 2027 (USD Million)

Table 15 Europe Intravenous Immunoglobulin Market, 2016 – 2027 (USD Million)

Table 16 France Intravenous Immunoglobulin Market, 2016 – 2027 (USD Million)

Table 17 Germany Intravenous Immunoglobulin Market, 2016 – 2027 (USD Million)

Table 18 Asia Pacific Intravenous Immunoglobulin Market, 2016 – 2027 (USD Million)

Table 19 China Intravenous Immunoglobulin Market, 2016 – 2027 (USD Million)

Table 20 India Intravenous Immunoglobulin Market, 2016 – 2027 (USD Million)

Table 21 Latin America Intravenous Immunoglobulin Market, 2016 - 2027 (USD Million)

Table 22 MEA Intravenous Immunoglobulin Market, 2016 - 2027 (USD Million)

List Of Figures, Charts and Diagrams in Intravenous Immunoglobulin Market, By Disease Types (CIDP, Hypogammaglobulinemia, Congenital AIDS, Immunodeficiency diseases, Chronic Lymphocytic Leukaemia, Myasthenia Gravis, Multifocal motor neuropathy, and others), By Route (Intravenous and Subcutaneous) And Geography (North America, Europe, Asia Pacific, And Rest Of The World) – Analysis, Share, Trends, Size, & Forecast From 2016 – 2027- C

List of Figures

Figure 1 Research Methodology

Figure 2 Research Process Flow Chart

Figure 3 Comparative Analysis, by Geography, 2016-2025 (Value %)

Figure 4 Regulatory Framework Analysis

Figure 5 Value Chain Analysis Analysis

Figure 6 Intravenous Immunoglobulin Market, by Disease Types, 2016 – 2027 (USD Million)

Figure 7 Intravenous Immunoglobulin Market, by Geography, 2016 – 2027 (USD Million)

How to Buy...

Intravenous Immunoglobulin Market, By Disease Types (CIDP, Hypogammaglobulinemia, Congenital AIDS, Immunodeficiency diseases, Chronic Lymphocytic Leukaemia, Myasthenia Gravis, Multifocal motor neuropathy, and others), By Route (Intravenous and Subcutaneous) And Geography (North America, Europe, Asia Pacific, And Rest Of The World) – Analysis, Share, Trends, Size, & Forecast From 2016 - 2027- C

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/270587>

Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at bioportfolio97@gmail.com We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$3250** | Single User Price
- \$4650** | Site License Price
- \$5650** | Global License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.